Related content

A first-in-man phase I tolerability and pharmacokinetic study of the cyclin-dependent kinase-inhibitor AZD5438 in healthy male volunteers

By Camidge D.   Smethurst Dominic   Growcott Jim   Barrass Nigel   Foster John   Febbraro Salvatore   Swaisland Helen   Hughes Andrew  

Cancer Chemotherapy and Pharmacology, Vol. 60, Iss. 3, 2007-08 ,pp. : 391-398

Springer Publishing Company

Access to resources Recommend Favorite

X-Ray Crystallographic Studies of CDK2, a Basis for Cyclin-Dependent Kinase Inhibitor Design in Anti-Cancer Drug Research

By  

Current Medicinal Chemistry - Anti-Cancer Agents, Vol. 3, Iss. 1, 2003-01 ,pp. : 15-23

Bentham Science Publishers

Access to resources Recommend Favorite

Underexpression of Cyclin-Dependent Kinase (CDK) Inhibitors in Cervical Carcinoma

By Kim Y.T.   Cho N.H.   Park S.W.   Kim J.W.  

Gynecologic Oncology, Vol. 71, Iss. 1, 1998-10 ,pp. : 38-45

Elsevier

Access to resources Recommend Favorite

A phase I pharmacodynamic study of the effects of the cyclin-dependent kinase-inhibitor AZD5438 on cell cycle markers within the buccal mucosa, plucked scalp hairs and peripheral blood mononucleocytes of healthy male volunteers

By Camidge D.   Pemberton Mike   Growcott Jim   Amakye Dereck   Wilson David   Swaisland Helen   Forder Cheryl   Wilkinson Robert   Byth Kate   Hughes Andrew  

Cancer Chemotherapy and Pharmacology, Vol. 60, Iss. 4, 2007-09 ,pp. : 479-488

Springer Publishing Company

Access to resources Recommend Favorite

Clinical and laboratory studies of the novel cyclin-dependent kinase inhibitor dinaciclib (SCH 727965) in acute leukemias

By Gojo Ivana   Sadowska Mariola   Walker Alison   Feldman Eric   Iyer Swaminathan   Baer Maria   Sausville Edward   Lapidus Rena   Zhang Da   Zhu Yali   Jou Ying-Ming   Poon Jennifer   Small Karen   Bannerji Rajat  

Cancer Chemotherapy and Pharmacology, Vol. 72, Iss. 4, 2013-10 ,pp. : 897-908

Springer Publishing Company

Access to resources Recommend Favorite